Phase 2 Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with advanced stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed by a tissue or cell sample.
• People whose cancer has stopped responding to a first round of treatment that included both chemotherapy and immune-based therapy, and who received that immune-based therapy for at least 3 months.
• People who have at least one tumour that can be measured on a scan and has not been treated with radiotherapy (or, if it was previously in a treated area, has since been confirmed to have grown back).
• People with a general health and activity level rated at 0 or 1 on a standard medical scale (meaning fully active or able to carry out light work).
• People with an expected survival of at least 12 weeks.
• People whose blood counts, liver function, and kidney function meet the specific levels required by the trial (confirm with trial site for exact values).
• People who are willing and able to use an approved form of contraception during treatment and for at least 6 months after the last dose of study medication — this applies to women who could become pregnant and to men whose partners could become pregnant.
• People who are willing to take part voluntarily, sign a consent form, follow the study requirements, and attend follow-up visits.

Who may not be able to join:

• People who have had a hole or abnormal opening in the digestive tract (perforation or fistula) within the 6 months before starting the trial.
• People who have fluid build-up around the lungs, heart, or abdomen that cannot be controlled and keeps needing to be drained.
• People who have had an allergic reaction to any ingredient in the study drug Adebrelimab.
• People who have taken another experimental drug within 4 weeks before the trial starts, or within 5 half-lives of that drug (confirm with trial site).
• People who are currently enrolled in another clinical trial that involves an active treatment (observational studies or follow-up-only stages may be exceptions — confirm with trial site).
• People who have received any anti-cancer treatment — including radiotherapy, chemotherapy, immunotherapy, hormone therapy, targeted therapy, or similar — within 2 weeks before starting the trial.
• People who have needed regular, higher-dose steroid medication (equivalent to more than 10 mg of prednisone per day) within 2 weeks before starting the trial, with some exceptions (confirm with trial site).
• People who have received an anti-cancer vaccine or a live vaccine within 4 weeks before starting the trial.
• People who have had major surgery or a serious injury within 4 weeks before starting the trial.
• People who have previously been treated with paclitaxel-based (taxane) chemotherapy drugs.
• People who still have significant side effects from previous cancer treatment that have not returned to a mild level (with the exception of hair loss).
• People who have active cancer spread to the brain or spinal cord.
• People who have active autoimmune diseases or a history of certain autoimmune conditions such as lung inflammation, colitis, hepatitis, or similar (some exceptions apply — confirm with trial site).
• People with a weakened immune system, a positive HIV test, other immune deficiency conditions, or a history of organ or bone marrow transplant; also people with active hepatitis B with virus levels above a certain threshold.
• People with serious, uncontrolled heart conditions, including moderate-to-severe heart failure, unstable chest pain, a heart attack within the past year, or significant uncontrolled irregular heartbeat.
• People who have had a severe infection within 4 weeks before starting the trial, or who have signs of active infection or are taking antibiotic treatment within 2 weeks before starting (preventive antibiotic use may be an exception — confirm with trial site).
• People with a history of scarring or inflammation of the lung tissue (interstitial lung disease), with some exceptions (confirm with trial site).
• People with active tuberculosis or a history of tuberculosis that was not properly treated.
• People who have been diagnosed with another cancer within the past 5 years, except for certain very low-risk skin cancers or cervical pre-cancers that have been fully treated.
• People who are pregnant or breastfeeding.
• People who, in the opinion of the medical team, have other serious illnesses, significant abnormal test results, or personal circumstances that could put their safety at risk or affect the trial.

Important: Always verify eligibility with the trial site directly before applying.